JP2005504783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504783A5 JP2005504783A5 JP2003524978A JP2003524978A JP2005504783A5 JP 2005504783 A5 JP2005504783 A5 JP 2005504783A5 JP 2003524978 A JP2003524978 A JP 2003524978A JP 2003524978 A JP2003524978 A JP 2003524978A JP 2005504783 A5 JP2005504783 A5 JP 2005504783A5
- Authority
- JP
- Japan
- Prior art keywords
- iloperidone
- isoxazol
- piperidin
- benzo
- propoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 229960003162 iloperidone Drugs 0.000 claims description 3
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims 2
- SBKZGLWZGZQVHA-INIZCTEOSA-N (1s)-1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol Chemical compound COC1=CC([C@H](C)O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 SBKZGLWZGZQVHA-INIZCTEOSA-N 0.000 claims 1
- -1 6-Fluoro-benzo [d] isoxazol-3-yl Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229910000085 borane Inorganic materials 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31639001P | 2001-08-31 | 2001-08-31 | |
| PCT/EP2002/009700 WO2003020707A1 (en) | 2001-08-31 | 2002-08-30 | Optical isomers of an iloperidone metabolite |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009281094A Division JP2010100633A (ja) | 2001-08-31 | 2009-12-11 | イロペリドン代謝産物の光学異性体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005504783A JP2005504783A (ja) | 2005-02-17 |
| JP2005504783A5 true JP2005504783A5 (enExample) | 2009-08-27 |
Family
ID=23228843
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524978A Withdrawn JP2005504783A (ja) | 2001-08-31 | 2002-08-30 | イロペリドン代謝産物の光学異性体 |
| JP2009281094A Withdrawn JP2010100633A (ja) | 2001-08-31 | 2009-12-11 | イロペリドン代謝産物の光学異性体 |
| JP2013017050A Withdrawn JP2013116905A (ja) | 2001-08-31 | 2013-01-31 | イロペリドン代謝産物の光学異性体 |
| JP2013142873A Pending JP2013227335A (ja) | 2001-08-31 | 2013-07-08 | イロペリドン代謝産物の光学異性体 |
| JP2015156358A Pending JP2015227368A (ja) | 2001-08-31 | 2015-08-06 | イロペリドン代謝産物の光学異性体 |
| JP2015156359A Pending JP2015214577A (ja) | 2001-08-31 | 2015-08-06 | イロペリドン代謝産物の光学異性体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009281094A Withdrawn JP2010100633A (ja) | 2001-08-31 | 2009-12-11 | イロペリドン代謝産物の光学異性体 |
| JP2013017050A Withdrawn JP2013116905A (ja) | 2001-08-31 | 2013-01-31 | イロペリドン代謝産物の光学異性体 |
| JP2013142873A Pending JP2013227335A (ja) | 2001-08-31 | 2013-07-08 | イロペリドン代謝産物の光学異性体 |
| JP2015156358A Pending JP2015227368A (ja) | 2001-08-31 | 2015-08-06 | イロペリドン代謝産物の光学異性体 |
| JP2015156359A Pending JP2015214577A (ja) | 2001-08-31 | 2015-08-06 | イロペリドン代謝産物の光学異性体 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20050020632A1 (enExample) |
| EP (2) | EP2305656B1 (enExample) |
| JP (6) | JP2005504783A (enExample) |
| AT (1) | ATE518845T1 (enExample) |
| CY (2) | CY1112039T1 (enExample) |
| DK (2) | DK2305656T3 (enExample) |
| ES (2) | ES2398434T3 (enExample) |
| PT (2) | PT2305656E (enExample) |
| WO (1) | WO2003020707A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2358416T3 (es) | 2001-10-30 | 2011-05-10 | Novartis Ag | Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella. |
| SI1497266T1 (sl) | 2002-03-27 | 2008-10-31 | Glaxo Group Ltd | Derivati kinolina in njihova uporaba kot ligandi 5-ht6 |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| EP1558582B1 (en) | 2003-07-22 | 2005-12-21 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
| EP1799865B1 (en) | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| US20100063093A1 (en) | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| US20070262395A1 (en) | 2006-05-11 | 2007-11-15 | Gibbons Jasper S | Memory cell access devices and methods of making the same |
| US8008144B2 (en) | 2006-05-11 | 2011-08-30 | Micron Technology, Inc. | Dual work function recessed access device and methods of forming |
| US20090306137A1 (en) | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| WO2008121899A2 (en) | 2007-03-29 | 2008-10-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
| US20150259747A1 (en) | 2007-03-29 | 2015-09-17 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
| WO2008128166A1 (en) * | 2007-04-13 | 2008-10-23 | Concert Pharmaceuticals Inc. | Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds |
| EP3075865B1 (en) | 2007-05-18 | 2018-05-09 | Vanda Pharmaceuticals Inc. | Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms |
| US8652776B2 (en) | 2007-09-10 | 2014-02-18 | Vanda Pharmaceuticals, Inc. | Prediction of QT prolongation based on SNP genotype |
| EP2254564A1 (en) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| CA2709104C (en) | 2007-12-13 | 2017-06-13 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
| US8729100B2 (en) | 2007-12-13 | 2014-05-20 | Vanda Pharmaceuticals, Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
| US20110061014A1 (en) | 2008-02-01 | 2011-03-10 | Energyhub | Interfacing to resource consumption management devices |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| US7824986B2 (en) | 2008-11-05 | 2010-11-02 | Micron Technology, Inc. | Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions |
| JP5881597B2 (ja) | 2009-04-06 | 2016-03-09 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ｑｔ延長に対する素因を予測する方法 |
| EP2416779B1 (en) | 2009-04-06 | 2016-03-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof |
| ES2604102T3 (es) | 2009-04-06 | 2017-03-03 | Vanda Pharmaceuticals Inc. | Método de tratamiento basado en polimorfismos del gen KCNQ1 |
| WO2010117941A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof |
| BR112012015084A2 (pt) | 2009-12-23 | 2017-03-07 | Lupin Ltd | composição farmacêutica de liberação lenta de iloperidone |
| US9000221B2 (en) | 2010-09-07 | 2015-04-07 | Symed Labs Limited | Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof |
| WO2012063269A2 (en) | 2010-11-12 | 2012-05-18 | Cadila Healthcare Limited | Process for preparing iloperidone |
| CA2865845C (en) | 2012-03-14 | 2020-02-18 | Vanda Pharmaceuticals Inc. | An iloperidone metabolite for use in the treatment of psychiatric disorders |
| CA2976383C (en) | 2015-02-17 | 2023-05-23 | Vanda Pharmaceuticals Inc. | Iloperidone for the treatment of schizophrenia |
| HK1245660A1 (zh) | 2015-06-12 | 2018-08-31 | Axovant Sciences Gmbh | 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物 |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| CN114941015B (zh) * | 2019-02-21 | 2024-05-03 | 深圳艾欣达伟医药科技有限公司 | 制造高镜像选择性二级醇的方法 |
| US11607408B2 (en) | 2019-10-15 | 2023-03-21 | Vanda Pharmaceuticals Inc. | Method of treatment of schizophrenia |
| WO2023201182A1 (en) | 2022-04-13 | 2023-10-19 | Vanda Pharmaceuticals Inc. | Treatment of parkinson's disease and parkinson's disease psychosis |
| WO2024137439A1 (en) | 2022-12-19 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia |
| KR20260019503A (ko) | 2023-06-02 | 2026-02-10 | 반다 파마슈티칼즈, 인코퍼레이티드. | 일로페리돈을 사용한 치료 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| ES2076253T3 (es) * | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| JPH05286868A (ja) | 1992-04-03 | 1993-11-02 | Kiyoshi Okawa | 制がん剤複合体およびそのスクリーニング法 |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US6172099B1 (en) * | 1997-07-03 | 2001-01-09 | Asahi Kasei Kogyo Kabushiki Kaisha | Tricyclic compounds having saturated rings and medicinal compositions containing the same |
| EP1551393A4 (en) | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
-
2002
- 2002-08-30 ES ES10009915T patent/ES2398434T3/es not_active Expired - Lifetime
- 2002-08-30 PT PT100099159T patent/PT2305656E/pt unknown
- 2002-08-30 US US10/488,128 patent/US20050020632A1/en not_active Abandoned
- 2002-08-30 DK DK10009915.9T patent/DK2305656T3/da active
- 2002-08-30 ES ES02767454T patent/ES2370634T3/es not_active Expired - Lifetime
- 2002-08-30 JP JP2003524978A patent/JP2005504783A/ja not_active Withdrawn
- 2002-08-30 EP EP10009915A patent/EP2305656B1/en not_active Expired - Lifetime
- 2002-08-30 AT AT02767454T patent/ATE518845T1/de active
- 2002-08-30 EP EP02767454A patent/EP1425272B1/en not_active Expired - Lifetime
- 2002-08-30 DK DK02767454.8T patent/DK1425272T3/da active
- 2002-08-30 WO PCT/EP2002/009700 patent/WO2003020707A1/en not_active Ceased
- 2002-08-30 PT PT02767454T patent/PT1425272E/pt unknown
-
2009
- 2009-03-13 US US12/403,755 patent/US7977356B2/en not_active Expired - Lifetime
- 2009-12-11 JP JP2009281094A patent/JP2010100633A/ja not_active Withdrawn
-
2011
- 2011-04-28 US US13/096,015 patent/US8314129B2/en not_active Expired - Lifetime
- 2011-11-02 CY CY20111101053T patent/CY1112039T1/el unknown
-
2012
- 2012-10-26 US US13/661,609 patent/US20130296366A1/en not_active Abandoned
-
2013
- 2013-01-23 CY CY20131100058T patent/CY1113550T1/el unknown
- 2013-01-31 JP JP2013017050A patent/JP2013116905A/ja not_active Withdrawn
- 2013-07-08 JP JP2013142873A patent/JP2013227335A/ja active Pending
-
2015
- 2015-08-06 JP JP2015156358A patent/JP2015227368A/ja active Pending
- 2015-08-06 JP JP2015156359A patent/JP2015214577A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1425272E (pt) | Isómeros óticos de um metabolito de iloperidona | |
| JP2006514626A5 (enExample) | ||
| CN100415736C (zh) | 喹啉基丙基哌啶衍生物以及其作为抗微生物剂的应用 | |
| JP2008513516A5 (enExample) | ||
| NO20082059L (no) | Ny polymorf form og den amorfe formen av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid | |
| JP2009514836A5 (enExample) | ||
| JP2005053931A5 (enExample) | ||
| WO2005060940A3 (de) | Verfahren zur herstellung einer festen, oral applizierbaren pharmazeutischen zusammensetzung | |
| JP2007523181A5 (enExample) | ||
| JP2009510064A5 (enExample) | ||
| JP2009514835A5 (enExample) | ||
| JP2013519680A5 (enExample) | ||
| TW530054B (en) | New piperazine and piperidine compounds | |
| JP2004518677A5 (enExample) | ||
| EP2103214A4 (en) | FLOOR OR SEED TREATMENT AGENT CONTAINING A CHINOLINE COMPOUND OR A SALT THEREOF AS ACTIVE SUBSTANCE OR METHOD FOR COMBATING PLANT DISEASES USING THE AGENT | |
| CA2727378A1 (en) | New co-crystal compound of rivaroxaban and malonic acid | |
| AU2014364783A1 (en) | Fused heterocyclic compounds as ion channel modulators | |
| JP2008516922A5 (enExample) | ||
| JP2011500673A5 (enExample) | ||
| JP2004507501A5 (enExample) | ||
| JP2006521393A5 (enExample) | ||
| NO20070974L (no) | Substituerte N-acyl-2-aminotiazoler | |
| JP2008538583A5 (enExample) | ||
| JP2004517151A5 (enExample) | ||
| JP2006510659A5 (enExample) |